BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a strong-buy rating in a report published on Friday.

A number of other research firms have also commented on SRPT. JPMorgan Chase upped their price target on Sarepta Therapeutics from $75.00 to $95.00 and gave the company an overweight rating in a research report on Wednesday, March 14th. Royal Bank of Canada reaffirmed a buy rating and set a $91.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. SunTrust Banks increased their target price on Sarepta Therapeutics to $95.00 and gave the stock a buy rating in a research report on Friday, March 16th. Morgan Stanley lowered Sarepta Therapeutics from an overweight rating to an equal weight rating and increased their target price for the stock from $64.00 to $87.00 in a research report on Wednesday, March 21st. Finally, Credit Suisse Group reissued a hold rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research report on Monday, March 12th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $78.87.

How to Become a New Pot Stock Millionaire

SRPT opened at $78.46 on Friday. The company has a market cap of $5,250.25, a price-to-earnings ratio of -47.84 and a beta of 1.28. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. Sarepta Therapeutics has a one year low of $28.82 and a one year high of $84.37.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The business had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The company’s revenue for the quarter was up 961.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.71) EPS. equities research analysts forecast that Sarepta Therapeutics will post -1.18 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of SRPT. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sarepta Therapeutics by 39.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 2,493 shares in the last quarter. Prentiss Smith & Co. Inc. bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $199,000. Arrowstreet Capital Limited Partnership bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $217,000. Finally, Aperio Group LLC bought a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $219,000. 84.98% of the stock is owned by institutional investors.

WARNING: “Sarepta Therapeutics (SRPT) Rating Increased to Strong-Buy at BidaskClub” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/04/17/sarepta-therapeutics-srpt-rating-increased-to-strong-buy-at-bidaskclub.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.